Business
Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2025 Financial Results
SOUTH SAN FRANCISCO, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biotechnology company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today reported recent business progress and financial results for the third quarter 2025. “Our Phase 2 B-SUPREME study of pevifoscorvir sodium (pevy) is enrolling nicely, with subjects dosed across a number of countries, including the U.S., China
About this update from Aligos Therapeutics, Inc.
[{"type":"image","alt":"Aligos Therapeutics","displaySize":"","headline":null,"caption":"Aligos Therapeutics","className":"","disableSlideshowImg":false,"size":{"original":{"width":150,"height":50,"url":"https://media.zenfs.com/en/globenewswire.com/209c9435fdfab4fa4ff642c123fac955"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/L8133ghONMF7WN.yZV6tsw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIxMDtoPTcwO2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/209c9435fdfab4fa4ff642c123fac955","width":150,"height":50}},"lazy":false},{"type":"text","content":"SOUTH SAN FRANCISCO, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biotechnology company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today reported recent business progress and financial results for the third quarter 2025.","length":343,"tagName":"p"},{"type":"text","content":"“Our Phase 2 B-SUPREME study of pevifoscorvir sodium (pevy) is enrolling nicely, with subjects dosed across a number of countries, including the U.S., China, Hong Kong, and Canada,” stated Lawrence Blatt, Ph.D., M.B.A., Chairman, President, and Chief Executive Officer of Aligos Therapeutics. “We are pleased with the progress to date and look forward to interim readouts in 2026. Importantly, we look forward to sharing additional pevy data next week at AASLD’s The Liver Meeting®. We maintain our enthusiasm regarding the potential for pevy as well as our entire development pipeline, including ALG-055009, which is in continued discussions with potential partners for obesity and MASH.”","length":689,"tagName":"p"},{"type":"text","content":"Recent Business Progress","length":24,"tagName":"p"},{"type":"text","content":"Pipeline Updates","length":16,"tagName":"p"},{"type":"text","content":"Pevifoscorvir sodium: Potential first-/best-in-class small molecule CAM-E for chronic hepatitis B virus (HBV) infection","length":119,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"The Phase 2 B-SUPREME study (NCT06963710) of pevifoscorvir sodium in subjects with chronic HBV infection dosed its first patient in August 2025.","length":144,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"The study is designed as a randomized, double-blind, active-controlled multicenter study evaluating the safet...